Abstracts tagged "Lipids and systemic sclerosis"

Abstract Number: 1731 • 2017 ACR/ARHP Annual Meeting
Abnormal Responses of γδ T Cell Subsets to Stimulation with Cardiolipin and Zoledronate in Systemic Sclerosis
Ilan Bank¹, Paul Fisch², Jose Villacorta Hidalgo³, Alexandra Balbir-Gurman⁴, Yolanda Braun-Moscovici⁵ and Helena Migalovich Sheikhet⁶, ¹Medicine, Maayenei Hayeshuah and Chaim Sheba Medical Center, Israel, Bnei Brak, Israel, ²3Department of Clinical Pathology, University of Freiburg Medical Center, Freiburg, Germany, ³Department of Clinical Pathology, University of Freiburg Medical Center, Freiburg, Germany, ⁴Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel, Haifa, Israel, ⁵B Shine Department of Rheumatology, Rambam Health Care Campus,. Rappaport Faculty of Medicine, Technion, Haifa, Israel, ⁶Medicine, Laboratory of Immunoregulation, Chaim Sheba Medical Center, Ramat Gan, Israel
Background/Purpose: Systemic sclerosis (SSc) is an auto-immune disorder leading to destructive tissue fibrosis. Abnormal responses of SSc T cells to lipid antigens and low molecular…
Abstract Number: 1879 • 2016 ACR/ARHP Annual Meeting
The Correlation Between Oxidized Low-Density Lipoprotein and Clinical Manifestations in Patients with Systemic Sclerosis
Masanari Kodera, Miho Koumura, Yuki Tsurumi, Yoshihito Tanaka, Yu Inasaka and Yumi Ito, Dermatology, Japan Community Health care Organization Chukyo Hospital, Nagoya, Japan
Background/Purpose: Oxidized low-density lipoprotein (LDL), especially malondialdehyde modified LDL (MDA-LDL) has attracted attention as a predictive serum marker for the secondary development of atherosclerotic lesions.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].